Agenda

CheckMate-032:

Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).

POSTER SESSION | Abstract 4010 | CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). Poster Board: #2

Presenter: PrenYelena Yuriy Janjigian, MD

Discussão15:00 - 16:15, Hall D1

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 8:00- 11:30
Localidade Hall A

Biliary tract cancer: the new and the old

Chair(s): Mary Frances Mulcahy, MD, Northwestern University

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 16:45 - 18:00
Localidade E450ab

Molecular Profiling and Clinical Impact: A Target-Rich Disease.

Mary Frances Mulcahy, MD

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 16:45 - 17:05

Nivolumab (nivo) vs docetaxel (doc)

in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

POSTER SESSION | Abstract 9025 | Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

Poster Board: #348

Presenter: Hossein Borghaei, DO, MS

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 8:00- 11:30
Localidade Hall A

Changing Epidemiology of BTC: A Focus on Geographic, Ethnic, and Age Differences

John A. Bridgewater, MD

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 17:05 - 17:25

Locally Advanced Biliary Tract Cancer: A Case in Point

Karyn A. Goodman, MD, MS

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 17:25 - 17:45

CheckMate 012:

Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

ORAL ABSTRACT SESSION | Abstract 3001 | CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.

Presenter: Matthew David Hellmann, MD

Informação Adicional

Data de Início sábado, 04 junho 2016
Data de Fim sábado, 04 junho 2016
Horário 13:27- 13:39
Localidade Hall B1

Checkmate 032:

Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

CLINICAL SCIENCE SYMPOSIUM | Abstract 100 | Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

Presenter: Scott Joseph Antonia, MD, PhD - Presenter